You are here: Industry Insights > Novartis

News List

Novartis renews drug donation of Egaten® (triclabendazole) until 2022 worldpharmanews
July 25, 2018
Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten® (triclabendazole) until 2022.
Novartis Enters into License Agreement with Galapagos, MorphoSys americanpharmaceuticalreview
July 24, 2018
Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen and MorphoSys regarding their compound MOR106.
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys fiercebiotech
July 23, 2018
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106.
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys fiercebiotech
July 20, 2018
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106. The deal positions Novartis to take MOR106 forward in atopic dermatitis and other indications, handing over up to €850
US, EU filings imminent for Novartis’ MS therapy siponimod pharmatimes
July 20, 2018
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.
Tasigna cleared for use in children with rare leukemia pharmatimes
July 20, 2018
The US Food and Drug Administration is allowing use of Novartis’ Tasigna to treat paediatric patients with a rare form of leukaemia.
Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug pharmatimes
July 20, 2018
Novartis has signed an exclusive global license agreement with Galapagos and MorphoSys for MOR106, a novel antibody directed against IL-17C.
Under scrutiny for Cohen deal, Novartis calls off further price hikes in 2018 fiercepharma
July 19, 2018
Even before Pfizer faced the wrath of U.S. President Donald Trump for July price hikes, Novartis decided against putting through more of its own increases in 2018, its helmsman told analysts on Wednesday.
Novartis runs into Kymriah production glitch in new DLBCL indication fiercepharma
July 19, 2018
Novartis, whose personalized CAR-T cancer treatment Kymriah won an approval in May to treat relapsed large B-cell lymphoma, said today it has run into some manufacturing issues around that condition.
Novartis snaps up AveXis in $8.7bn deal pharmatimes
July 17, 2018
Novartis is buying US gene therapy group AveXis in a deal valued at $8.7 billion.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page